German pharma major Bayer (BAYN: DE) took another step towards its goal of becoming a leader in cell and gene therapies by announcing a strategic collaboration and option agreement with Mammoth Biosciences.
Privately-held Californian firm Mammoth, which has a vision to unlock the full potential of new CRISPR systems, is to receive an upfront sum of $40 million from Bayer, as well as potential future milestone payments of more than $1 billion.
"Will allow us to unleash the full potential of our cell and gene therapy strategy"Mammoth’s gene-editing capability is a key enabling technology, as well as a stand-alone therapeutic modality.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze